For instance, in colorectal cancer, the presence of a RAS mutation signifies that therapies targeting the epidermal growth factor receptor (EGFR) are unlikely to be effective, allowing clinicians to avoid such treatments and instead focus on alternative therapeutic strategies that are better suited to the patient’s genetic profile. This evidence concerns the gene EGFR and colorectal cancer.